SUN-LB115 Is the Stepping-Down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-Controlled Diabetes on Advanced Insulin Therapy?

Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills P

Journal of the Endocrine Society8 May 2020

PMCIDPMC7209541PepBankPUB-98380921

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, the dulaglutide-containing step-down regimen reduced HbA1c versus multiple daily insulin injections at 16 weeks.
In plain wordsIn obese people with diabetes, the dulaglutide-containing regimen lowered average blood sugar more than multiple daily insulin injections at 16 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c at final follow-up
Study
n = 18
Comparator
Multiple daily insulin injections
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
8.25%
step-down, 16 weeks
HbA1c
9.7%
control, 16 weeks
Source sentences
Summary
However, A1c was significantly lower at 4 weeks (9.54% vs 7.31%; p=0.0088) and 16 weeks (9.7% vs 8.25%; p<0.001) in intervention group (n=10).
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092102
02HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, body weight decreased from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, weight decreased from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−16.38 Lbs
step-down, 16 weeks
Source sentences
Summary
In intervention group, compared to baseline, there was a significant decrease in weight (-16.38 Lbs; p=0.003), BMI (-3.06; p<0.001), LDL cholesterol (-15.7 mg/d; p=0.0378), total cholesterol (-18.5 mg/dL; p=0.0386), total daily insulin dose (-57.3 units; p<0.001) and a significant improvement
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092103
03HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, BMI decreased from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, body mass index decreased from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBMI change
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change
−3.06 BMI units
step-down, 16 weeks
Source sentences
Summary
In intervention group, compared to baseline, there was a significant decrease in weight (-16.38 Lbs; p=0.003), BMI (-3.06; p<0.001), LDL cholesterol (-15.7 mg/d; p=0.0378), total cholesterol (-18.5 mg/dL; p=0.0386), total daily insulin dose (-57.3 units; p<0.001) and a significant improvement
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092104
04HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, LDL cholesterol decreased from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, LDL cholesterol decreased from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLDL cholesterol change
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Measurements
LDL cholesterol change
−15.7 mg/d
step-down, 16 weeks
Source sentences
Summary
In intervention group, compared to baseline, there was a significant decrease in weight (-16.38 Lbs; p=0.003), BMI (-3.06; p<0.001), LDL cholesterol (-15.7 mg/d; p=0.0378), total cholesterol (-18.5 mg/dL; p=0.0386), total daily insulin dose (-57.3 units; p<0.001) and a significant improvement
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092105
05HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, total cholesterol decreased from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, total cholesterol decreased from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTotal cholesterol change
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Measurements
Total cholesterol change
−18.5 mg/dL
step-down, 16 weeks
Source sentences
Summary
In intervention group, compared to baseline, there was a significant decrease in weight (-16.38 Lbs; p=0.003), BMI (-3.06; p<0.001), LDL cholesterol (-15.7 mg/d; p=0.0378), total cholesterol (-18.5 mg/dL; p=0.0386), total daily insulin dose (-57.3 units; p<0.001) and a significant improvement
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092106
06HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, daily insulin dose decreased from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, daily insulin dose decreased from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDaily insulin dose change
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Insulin dose change
−57.3 units
step-down, 16 weeks
Source sentences
Summary
In intervention group, compared to baseline, there was a significant decrease in weight (-16.38 Lbs; p=0.003), BMI (-3.06; p<0.001), LDL cholesterol (-15.7 mg/d; p=0.0378), total cholesterol (-18.5 mg/dL; p=0.0386), total daily insulin dose (-57.3 units; p<0.001) and a significant improvement
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092107
07HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, total treatment satisfaction improved from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, overall treatment satisfaction improved from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDM-SAT total score
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Measurements
DM-SAT total score change
45.3 points
step-down, 16 weeks
Source sentences
Summary
and a significant improvement in DM-SAT patient satisfaction 0-100 scores - total score (+45.3; p <0.001) and subscale scores (Convenience +35.28, p =0.019; Lifestyle +35.8, p=0.0052; Medical control +51.3, p<0.001; Wellbeing +47.2,p=0.0091) at 16 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092108
08HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, treatment convenience satisfaction improved from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, satisfaction with treatment convenience improved from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDM-SAT convenience score
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Measurements
Convenience score change
35.28 points
step-down, 16 weeks
Source sentences
Summary
and a significant improvement in DM-SAT patient satisfaction 0-100 scores - total score (+45.3; p <0.001) and subscale scores (Convenience +35.28, p =0.019; Lifestyle +35.8, p=0.0052; Medical control +51.3, p<0.001; Wellbeing +47.2,p=0.0091) at 16 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092109
09HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, lifestyle satisfaction improved from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, lifestyle satisfaction improved from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDM-SAT lifestyle score
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Measurements
Lifestyle score change
35.8 points
step-down, 16 weeks
Source sentences
Summary
and a significant improvement in DM-SAT patient satisfaction 0-100 scores - total score (+45.3; p <0.001) and subscale scores (Convenience +35.28, p =0.019; Lifestyle +35.8, p=0.0052; Medical control +51.3, p<0.001; Wellbeing +47.2,p=0.0091) at 16 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092110
10HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, medical-control satisfaction improved from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, satisfaction with medical control improved from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDM-SAT medical control score
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Measurements
Medical control score change
51.3 points
step-down, 16 weeks
Source sentences
Summary
and a significant improvement in DM-SAT patient satisfaction 0-100 scores - total score (+45.3; p <0.001) and subscale scores (Convenience +35.28, p =0.019; Lifestyle +35.8, p=0.0052; Medical control +51.3, p<0.001; Wellbeing +47.2,p=0.0091) at 16 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092111
11HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, wellbeing satisfaction improved from baseline with the dulaglutide-containing step-down regimen.
In plain wordsIn obese people with diabetes, wellbeing satisfaction improved from baseline with the dulaglutide-containing regimen.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDM-SAT wellbeing score
Study
n = 10
Comparator
Baseline
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Measurements
Wellbeing score change
47.2 points
step-down, 16 weeks
Source sentences
Summary
and a significant improvement in DM-SAT patient satisfaction 0-100 scores - total score (+45.3; p <0.001) and subscale scores (Convenience +35.28, p =0.019; Lifestyle +35.8, p=0.0052; Medical control +51.3, p<0.001; Wellbeing +47.2,p=0.0091) at 16 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092112
12HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In obese diabetes patients, the dulaglutide-containing step-down regimen reduced HbA1c versus multiple daily insulin injections at 4 weeks.
In plain wordsIn obese people with diabetes, the dulaglutide-containing regimen lowered average blood sugar more than multiple daily insulin injections at 4 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c at early follow-up
Study
n = 18
Comparator
Multiple daily insulin injections
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
7.31%
step-down, 4 weeks
HbA1c
9.54%
control, 4 weeks
Source sentences
Summary
However, A1c was significantly lower at 4 weeks (9.54% vs 7.31%; p=0.0088) and 16 weeks (9.7% vs 8.25%; p<0.001) in intervention group (n=10).
2 context sentences(design, population, supporting numbers)
Summary · context
Research Design: This pilot, prospective, randomized, open-label, controlled, parallel-group trial enrolled 22 obese patients with T2DM on AIT, who had BMI ≥30 kg/m2, A1c >8% and eGFR >45.
Summary · context
In the intervention group, all prandial insulin injections were discontinued; but the patient remained on the basal insulin and metformin to which SGLT2i, Empagliflozin, and GLP1 RA, Dulaglutide, were added.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9838092101

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.